Allakos Inc. Overview
Pro stress-test →Allakos is a clinical stage biotechnology company that develops innovative therapeutics which target immunomodulatory receptors for the treatment of allergic, inflammatory and proliferative diseases. The company was acquired on May 15, 2025 by Concentra Biosciences following a strategic consolidation in the immunomodulatory therapeutics sector.
Strategic Profile
Pro stress-test →Allakos' primary product candidate is Antolimab (AK002), an investigational monoclonal antibody that selectively targets Siglec-8, a receptor found on mast cells and eosinophils, which play a key role in various allergic and inflammatory conditions. The company's R&D efforts are concentrated on conditions such as Eosinophilic Gastrointestinal Diseases (EGIDs), where Antolimab met all primary and secondary endpoints in a Phase 2 study, leading to the initiation of a Phase 3 study.
Competitive Landscape
Pro stress-test →Allakos competes with companies including Corvus Pharmaceuticals, Cogent Biosciences, Marker Therapeutics, Kite Pharma, and Coherus Oncology in the antibody therapeutics and immunomodulatory space, though most competitors target different receptor pathways or disease indications.
Industry Context
Allakos Inc. operates in Monoclonal antibody therapeutics for inflammatory diseases.
Key facts
Founded: 2012 · Headquarters: San Carlos, California, US · Employees: 61 · Market cap: $29.7M